SCHEMBL7101286

SCHEMBL7101286

CNC(=O)CC(=O)c1ccco1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.61
FEN1 P39748 1/20 0.61
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
ALDH1A1 P00352 6/20 0.51
HPGD P15428 4/20 0.51
POLB P06746 4/20 0.51
ALOX15 P16050 3/20 0.51
HSD17B10 Q99714 3/20 0.51
RECQL P46063 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 1/20 0.51
PTPN1 P18031 1/20 0.50
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
CYP2D6 P10635 1/20 0.47
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320074 0.84 ERCC5 (0.74) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL5158109 0.82 ERCC5 (0.57) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL7070914 0.82 ERCC5 (0.71) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL183688 0.81 ERCC5 (0.65) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL12926147 0.80 ERCC5 (0.54) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL1651850 0.80 CES2 (0.70) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL10356158 0.79 ERCC5 (0.62) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL10356501 0.79 ERCC5 (0.62) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL6510709 0.79 ERCC5 (0.72) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL574955 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ERCC5 1067/4885FEN1 1305/4885CES2 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.